Therapeutic Proteins and Oral Vaccines Market, by Drug Class (Therapeutic Proteins (Growth Factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Coagulation Factors, and Others) and Oral Vaccines (Live Attenuated Vaccine, Inactivated Vaccine, Recombi

Therapeutic Proteins and Oral Vaccines Market, by Drug Class (Therapeutic Proteins (Growth Factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Coagulation Factors, and Others) and Oral Vaccines (Live Attenuated Vaccine, Inactivated Vaccine, Recombinant Vaccine, and Others), by Application (Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, and Others), by Distribution Channel Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Oral administration of vaccines is the most convenient way of vaccination, owing to the factors such as oral vaccines are non-invasive, safe, and suitable for all age groups, especially children. Oral vaccines are mostly preferred for mass vaccination and are mostly liquid filled in sachet or blister. Oral vaccines are commonly available for diseases such as typhoid, cholera, adenovirus, rotavirus, and others.
Therapeutic proteins can be used to replace a protein that is abnormal or deficient in a particular disease. They can also augment the body’s supply of a beneficial protein to help reduce the impact of disease or chemotherapy. Genetically engineered proteins can closely resemble the natural proteins they replace, or they can be enhanced by adding sugars or other molecules that extend the protein’s duration of therapeutic activity in patients.
Market Dynamics
Key companies focusing on product approvals of oral vaccines and therapeutic proteins, is expected to drive the global therapeutic proteins and oral vaccines market. For instance, in July 2018, Emergent BioSolutions Inc. announced that it received marketing authorization from European Medicine Agency for its oral typhoid vaccine Vivotif (Typhoid Vaccine Live Oral Ty21a) in five European countries such as France, Portugal, Poland, Czech Republic, and Slovakia. Moreover, in May 2018, Amgen Inc. received the U.S. Food and Drug Administration approval for Aimovig (erenumab-aooe), indicated for preventive treatment of migraine in adults.
Key features of the study:
This report provides in-depth analysis of the global therapeutic proteins and oral vaccines market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
It profiles leading players in the global therapeutic proteins and oral vaccines based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
The global therapeutic proteins and oral vaccines market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
Stakeholders would greatly benefit in decision-making through various strategy matrices used in analyzing the global therapeutic proteins and oral vaccines market
Detailed Segmentation:
Global Therapeutic Proteins and Oral Vaccine Market, By Drug Class :
Therapeutic Proteins
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Coagulation Factors
Others
Oral Vaccines
Live Attenuated Vaccine
Inactivated Vaccine
Recombinant Vaccine
Others
Global Therapeutic Proteins and Oral Vaccine Market, By Application :
Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Disease
Others
Global Therapeutic Proteins and Oral Vaccine Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Therapeutic Proteins and Oral Vaccine Market, By Region:
North America
By Drug Class:
Therapeutic Proteins
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Coagulation Factors
Others
Oral Vaccines
Live Attenuated Vaccine
Inactivated Vaccine
Recombinant Vaccine
Others
By Application :
Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Disease
Others
By Distribution Channel :
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Drug Class:
Therapeutic Proteins
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Coagulation Factors
Others
Oral Vaccines
Live Attenuated Vaccine
Inactivated Vaccine
Recombinant Vaccine
Others
By Application :
Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Disease
Others
By Distribution Channel :
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Class:
Therapeutic Proteins
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Coagulation Factors
Others
Oral Vaccines
Live Attenuated Vaccine
Inactivated Vaccine
Recombinant Vaccine
Others
By Application :
Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Disease
Others
By Distribution Channel :
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class:
Therapeutic Proteins
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Coagulation Factors
Others
Oral Vaccines
Live Attenuated Vaccine
Inactivated Vaccine
Recombinant Vaccine
Others
By Application :
Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Disease
Others
By Distribution Channel :
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Class:
Therapeutic Proteins
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Coagulation Factors
Others
Oral Vaccines
Live Attenuated Vaccine
Inactivated Vaccine
Recombinant Vaccine
Others
By Application :
Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Disease
Others
By Distribution Channel :
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
GCC
Israel
Rest of Middle East
Africa
By Drug Class:
Therapeutic Proteins
Growth Factors
Fusion Proteins
Monoclonal Antibodies
Hormones
Coagulation Factors
Others
Oral Vaccines
Live Attenuated Vaccine
Inactivated Vaccine
Recombinant Vaccine
Others
By Application :
Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Disease
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Abbott Laboratories.*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Amgen, Inc.
Biogen, Inc.
Eily, Lilly, and Company
F. Hoffmann-La Roche
Johnson and Johnson
Merck & Co.
Novo Nordisk
Pfizer, Inc.
Sanofi S.A.
Serum Institute of India Pvt. Ltd.
Emergent Biosolutions Inc.
TransAlgae
MigVax Ltd
Lumen Bioscience, Inc.

“*” marked represents similar segmentation in other categories in the respective section.